Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

Pharmacology and Therapeutics

Volumn 117, Issue 2, 2008, Pages 244-279

  Tracey, Daniel ^a   Klareskog, Lars ^b   Sasso, Eric H ^a   Salfeld, Jochen G ^a   Tak, Paul P ^c  

^a ABBOTT LABORATORIES   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Immune mediated inflammatory diseases; Inflammation; Mechanism of action; Rheumatoid arthritis; TNF antagonists; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FC RECEPTOR; GOLIMUMAB; INFLIXIMAB; LIGAND; LYMPHOTOXIN; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; APOPTOSIS; BONE DESTRUCTION; CARTILAGE DEGENERATION; CLINICAL TRIAL; CROHN DISEASE; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BONE AND BONES; CARTILAGE; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INFLAMMATION; LIGANDS; LYMPHOTOXIN-ALPHA; MOLECULAR STRUCTURE; POLYETHYLENE GLYCOLS; RECEPTORS, FC; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38549176118     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2007.10.001     Document Type: Review

References (330)

1. Agarwal A., Panda S., and Misra R. Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study. Ann Rheum Dis 63 (2004) 891-892
2. Alessandri C., Bombardieri M., Papa N., Cinquini M., Magrini L., Tincani A., et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy infliximab in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63 (2004) 1218-1221
3. Alexopoulou L., Pasparakis M., and Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 27 (1997) 2588-2592
4. Alexopoulou L., Pasparakis M., and Kollias G. Complementation of lymphotoxin alpha knockout mice with tumor necrosis factor-expressing transgenes rectifies defective splenic structure and function. J Exp Med 188 (1998) 745-754
5. Aloisi F., and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6 (2006) 205-217
6. Alsalameh S., Winter K., Al-Ward R., Wendler J., Kalden J.R., and Kinne R.W. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol 49 (1999) 278-285
7. Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34 (2005) 19-22
8. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 298 (2002) 1395-1401
9. Anolik J.H., Owen T., Barnard J., and Sanz I. Anti-tumor necrosis factor therapy in rheumatoid arthritis alters B lymphocyte dynamics. Arthritis Rheum 52 9 (2005) S677
10. Arend W., and Dayer J. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33 (1990) 305-315
11. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50 (2004) 3161-3169
12. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Cöster L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005) 1986-1992
13. Askling J., Fored C.M., Geborek P., Jacobsson L.T.H., van Vollenhoven R., Feltelius N., et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 65 (2006) 707-712
14. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66 (2007) 1339-1344
15. Atzeni F., Sarzi-Puttini P., Dell' Acqua D., de Portu S., Cecchini G., Cruini C., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8 (2006) R3
16. Atzeni F., Sarzi-Puttini P., Doria A., Iaccarino L., and Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun Rev 4 (2005) 144-152
17. Atzeni F., Turiel M., Capsoni F., Doria A., Meroni P., and Sarzi-Puttini P. Autoimmunity and anti-TNF-α agents. Ann N Y Acad Sci 1051 (2005) 559-569
18. Baecklund E., Askling J., Rosenquist R., Ekbom A., and Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16 (2004) 254-261
19. Baecklund E., Ekbom A., Sparén P., Feltelius N., and Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317 (1998) 180-181
20. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006) 692-701
21. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
22. Balkwill F., and Coussens L.M. Cancer: an inflammatory link. Nature 431 (2004) 405-406
23. Bang L.M., and Keating G.M. Adalimumab: a review of its use in rheumatoid arthritis. Biodrugs 18 (2004) 121-139
24. Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.J., Broger C., et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73 (1993) 431-445
25. Barrera P., Joosten L.A., den Broeder A.A., van de Putte L.B., van Riel P.L., and van den Berg W.B. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF-alpha in patients with rheumatoid arthritis. Ann Rheum Dis 60 (2001) 660-669
26. Barrera P., Oyen W.J.G., Boerman O.C., and van Riel P.L.C.M. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003) 825-828
27. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66 (2007) 921-926
28. Barthel H.R., Gille T., Halbsguth A., and Kramer M. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol 20 (2005) 1464-1465
29. Bathon J.M., Martin R.W., Fleischmann R., Tesser J.R., Schiff M., Keystone E., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (2000) 1586-1593
30. Baughman B.P., Drent M., Kavuru M., Judson M.A., Costabel U., du Bois R., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174 (2006) 795-802
31. Bazzoni F., and Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 334 (1996) 1717-1725
32. Bendele A.M., Chlipala E.S., Scherrer J., Frazier J., Sennello G., Rich W.J., et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 43 (2000) 2648-2659
33. Bendixen G., Hadidi T., Manthorpe R., Permin H., Struckmann J., Wilk A., et al. Antibodies against nuclear components in schistosomiasis. Results compared to values in patients with rheumatoid arthritis, systemic lupus erythematosus, and osteoarthrosis. Allergy 39 (1984) 107-113
34. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., and Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 54 (2006) 3782-3789
35. Bengmark S. Acute and "chronic" phase reaction: a mother of disease. Clin Nutr 23 (2004) 1256-1266
36. Berg L., Lampa J., Rogberg S., van Vollenhoven R., and Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 60 (2001) 133-139
37. Berry M.A., Hargadon B., Shelley M., Parker D., Shaw D.E., Green R.H., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354 (2006) 697-708
38. Bieber J., and Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 30 (2004) 257-270
39. Bischoff S.C., Lorentz A., Schwengberg S., Weier G., Raab R., and Manns M.P. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 44 (1999) 643-652
40. Bombardieri S., Ruiz A., Fardellone P., McKenna P., Unnebrink F., Oezer K., et al. Effectiveness of adalimumab in rheumatoid arthritis in patients with a history of TNF antagonists in clinical practice. Rheumatology 46 (2007) 1191-1199
41. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
42. Boyce B.F., Li P., Yao Z., Zhang Q., Badell I.R., Schwarz E.M., et al. TNFα and pathologic bone resorption. Keio J Med 54 (2005) 127-131
43. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
44. Brennan F.M., Browne K.A., Green P.A., Jaspar J.M., Maini R.N., and Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha cA2 therapy. Br J Rheumatol 36 (1997) 643-650
45. Brennan F.M., Chantry D., Jackson A., Maini R., and Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2 (1989) 244-247
46. Browning J.L., Allaire N., Ngam-ek A., Notidis E., Hunt J., Perrin S., et al. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 23 (2005) 539-550
47. Browning J.L., Dougas I., Ngam-ed A., Bourdon P.R., Ehrenfels B.N., Miatkowski K., et al. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J Immunol 154 (1995) 33-46
48. Browning J., Sizing I., Lawton P., Bourdon P., Rennert P., Majeau G., et al. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J Immunol 159 (1997) 3288-3298
49. Bryl E., Vallejo A.N., Matteson E.L., Witkowski J.M., Weyand C.M., and Goronzy J.J. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum 52 (2005) 2996-3003
50. Busse W.W., Banks-Schlegel A., and Wenzel S.E. Pathophysiology of severe asthma. J Allergy Clin Immunol 106 (2000) 1033-1042
51. Busse W.W., and Lemanske Jr. R.F. Asthma. N Engl J Med 344 (2001) 350-362
52. Butler D., Malfait A., Mason L., Warden P., Kollias G., Maini R., et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 159 (1997) 2867-2876
53. Caffieri S., Di Lisa F., Bolesani F., Facco M., Semenzato G., Dall'Acqua F., et al. The mitochondrial effects of novel apoptogenic molecules generated by psoralen photolysis as a crucial mechanism in PUVA therapy. Blood 109 (2007) 4988-4994
54. Cao D., Malmström V., Baecher-Allan C., Hafler D., Klareskog L., and Trollmo C. Isolation and functional characterization of regulatory T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 33 (2003) 215-223
55. Carmona L., Gómez-Reino J.J., Rodríguez-Valverde V., Montero D., Pascual-Gómez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52 (2005) 1766-1772
56. Carmona L., Gomez-Reino J.J., and BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8 (2006) R72
57. Carrasco R., Smith J.A., and Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 6 (2004) 137-146
58. Catrina A.I., af Klint E., Ernestam S., Catrina S.B., Makrygiannakis D., Botusan I., et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54 (2006) 76-81
59. Catrina A.I., Lampa J., Ernestam S., af Klint E., Bratt J., Klareskog L., et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 41 (2002) 484-489
60. Catrina A.I., Trollmo C., af Klint E., Engstrom M., Lampa J., Hermansson Y., et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52 1 (2005) 61-72
61. Chan F.K.-M., Chun H.J., Zheng L., Siegel R.M., Bui K.L., and Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288 (2000) 2351-2354
62. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163 (1999) 1521-1528
63. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., and Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43 (2000) 2382-2390
64. Chaudhary R., Butler M., Playford R.J., and Ghosh S. Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumab at 10 micrograms per ml concentration. Gastroenterology 130 4 (2006) A696
65. Chen H.A., Lin K.C., Chen C.H., Liao H.T., Wang H.P., Chang H.N., et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 35-39
66. Chin R.K., Lo J.C., Kim O., Blink S.E., Christiansen P.A., Peterson P., et al. Lymphotoxin pathway directs thymic Aire expression. Nat Immunol 4 (2003) 1121-1127
67. Chomarat P., Dantin C., Bennett L., Banchereau J., and Palucka A.K. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 171 (2003) 2262-2269
68. Choy E.H.S., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
69. Cohen P.S., Nakshatri H., Dennis J., Caragine T., Bianchi M., Cerami A., et al. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci U S A 93 (1996) 3967-3971
70. Cope A.P., Londei M., Chu N.R., Cohen S.B., Elliott M.J., Brennan F.M., et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94 (1994) 749-760
71. Cordiali-Fei P., Trento E., D'Agosto G., Bordignon V., Mussi A., Ardigo M., et al. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha. J Autoimmune Dis 3 (2006) 5
72. Cronstein B.N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57 (2005) 163-172
73. Crotti T.N., Ahern M.J., Lange K., Weedon H., Coleman M., Roberts P.J., et al. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. J Rheumatol 30 (2003) 2319-2324
74. Crowe P., VanArsdale T., Walter B., Ware C., Hession C., Ehrenfels B., et al. A lymphotoxin-beta-specific receptor. Science 264 (1994) 707-710
75. D'Alessio A., Al-Lamki R.S., Bradley J.R., and Pober J.S. Caveolae participate in tumor necrosis factor receptor 1 signaling and internalization in a human endothelial cell line. Am J Pathol 166 (2005) 1273-1282
76. Danks L., Sabokbar A., Gundle R., and Athanasou N.A. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 61 (2002) 916-921
77. D'Auria F., Rovere-Querini P., Giazzon M., Ajello P., Baldissera E., Manfredi A.A., et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 255 (2004) 409-418
78. de Rycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., and de Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52 (2005) 2192-2201
79. den Broeder A.A., Joosten L.A.B., Saxne T., Heinegard D., Fenner H., Miltenburg A.M.M., et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61 (2002) 311-318
80. Di Sabatino A., Ciccocioppo R., Cinque B., Millimaggi D., Morera R., Ricevuti L., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53 (2004) 70-77
81. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13 (2007) 156-163
82. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P., and British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
83. Doherty G.M., Jensen J.C., Alexander H.R., Buresh C.M., and Norton J.A. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110 (1991) 192-198
84. Dvorak H., Brown L., Detmar M., and Dvorak A. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 (1995) 1029-1039
85. Edwards III C.K., Bendele A.M., Reznikov L.I., Fantuzzi G., Chlipala E.S., Li L., et al. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor?. Arthritis Rheum 54 (2006) 2872-2885
86. Ehlers S., Hölscher C., Scheu S., Tertilt C., Hehlgans T., Suwinski J., et al. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol 170 (2003) 5210-5218
87. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200 (2004) 277-285
88. Eissner G., Kirchner S., Lindner H., Kolch W., Janosch P., Grell M., et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 164 (2000) 6193-6198
89. Eissner G., Kolch W., and Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 15 (2004) 353-366
90. Elkayam O., Caspi D., Reitblatt T., Charboneau D., and Rubins J.B. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33 (2004) 283-288
91. Elliott M.J., Maini R.N., Feldmann M., Long F.A., Charles P., Katsikis P., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36 (1993) 1681-1690
92. Elliott M., Maini R., Feldmann M., Kalden J., Antoni C., Smolen J., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
93. Enbrel (etanercept) prescribing information. Immunex Corporation, Thousand Oaks, CA (2007)
94. Engelmann H., Holtmann H., Brakebusch C., Avni Y., Sarov I., Nophar Y., et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265 (1990) 14497-14504
95. Engwerda C.R., Ato M., Stager S., Alexander C.E., Stanley A.C., and Kaye P.M. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection. Am J Pathol 165 (2004) 2123-2133
96. Evans T.J., Moyes D., Carpenter A., Martin R., Loetscher H., Lesslauer W., et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180 (1994) 2173-2179
97. Fava R.A., Notidis E., Hunt J., Szanya V., Ratcliffe N., Ngam-ek A., et al. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 171 (2003) 115-126
98. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2 (2002) 364-371
99. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Ann Rev Immunol 19 (2001) 163-196
100. Feldmann M., and Maini R.N. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 69 (2002) 12-18
101. Feldmann M., and Maini R.N. Lasker Clinical Medical Research Award: TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9 (2003) 1245-1250
102. Feldmann M., and Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 435 (2005) 612-619
103. Feuerherm A.J., Borset M., Seidel C., Sundan A., Leistad L., Ostensen M., et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 30 (2001) 229-234
104. Finckh A., Simard J.F., Gabay C., and Guerne P.-A. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65 (2006) 746-752
105. Fisher C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 334 (1996) 1697-1702
106. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-[alpha] is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 2 (1995) 561-572
107. Fossati G., and Nesbitt A.M. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870). Am J Gastroenterol 100 (2005) S299 (Suppl S)
108. Fossati G., and Nesbitt A.M. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol 100 (2005) S298-S299 (Suppl S)
109. Fraser A., Fearon U., Reece R., Emery P., and Veale D.J. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 44 (2001) 2024-2028
110. Friedmann E., Hauben E., Maylandt K., Schleeger S., Vreugde S., Lichtenthaler S.F., et al. SPPL2a and SPPL2b promote intramembrane proteolysis of TNF[alpha] in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 8 (2006) 843-848
111. Fu Y.-X., and Chaplin D.D. Development and maturation of secondary lymphoid tissues. Ann Rev Immunol 17 (1999) 399-433
112. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Sieper J., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66 (2007) iii2-iii22
113. Furst D.E., Wallis R., Broder M., and Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36 (2006) 159-167
114. Galustian C., Labarthe M.C., Bartlett J.B., and Dalgleish A.G. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 4 (2004) 1963-1970
115. Gelderman K.A., Lam S., and Gorter A. Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs. Expert Opin Biol Ther 5 (2005) 1593-1601
116. Genestier L., Paillot R., Fournel S., Ferraro C., Miossec P., and Revillard J.-P. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 102 (1998) 322-328
117. Genovese M.C., Kavanaugh A.F., Cohen S.B., Emery P., Sasso E.H., and Spencer-Green G.T. The relationship of radiographic progression to clinical response in patients with early RA treated with adalimumab (Humira®) plus MTX or MTX alone. Arthritis Rheum 52 (2005) S451 (Suppl)
118. Geusens P.P., Landewé R.B.M., Garnero P., Chen D., Dunstan C.R., Lems W.F., et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54 (2006) 1772-1777
119. Goedkoop A.Y., Kraan M.C., Picavet D.I., de Rie M.A., Teunissen M.B., Bos J.D., et al. Early effects of tumour necrosis factor {alpha} blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 63 (2004) 769-773
120. Goedkoop A.Y., Kraan M.C., Teunissen M.B., Picavet D.I., de Rie M.A., Bos J.D., et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 6 (2004) R326-R334
121. Gomez-Reino J., and Group C.L.B. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8 (2006) R29
122. Gommerman J.L., and Browning J.L. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 3 (2003) 642-655
123. Gordon K.B., Bonish B.K., Patel T., Leonardi C.L., and Nickoloff B.J. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 153 (2005) 945-953
124. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
125. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abello M.V., Lowes M.A., et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175 (2005) 2721-2729
126. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
127. Gramlick A., Fossati G., and Nesbitt A.M. Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF- alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor-specific bioassays. Gastroenterology 130 4 (2006) A697
128. Granneman R.G., Zhang Y., Noertersheuser P.A., Velagapudi R.B., Awni W.M., Locke C.S., et al. Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum 48 (2003) S140-S141
129. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 (1995) 793-802
130. Grell M., Wajant H., Zimmermann G., and Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. PNAS 95 (1998) 570-575
131. Gridley G., McLaughlin J.K., Ekbom A., Klareskog L., Adami H.-O., Hacker D.G., et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85 (1993) 307-311
132. Grivennikov S.I., Tumanov A.V., Liepinsh D.J., Kruglov A.A., Marakusha B.I., Shakhov A.N., et al. Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: protective and deleterious effects. Immunity 22 (2005) 93-104
133. Gudbrandsdottir S., Larsen R., Sorensen L.K., Nielsen S., Hansen M.B., Svenson M., et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 22 (2004) 118-124
134. Han J., Brown T., and Beutler B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level [published erratum appears in J Exp Med 171(3), 971-972]. J Exp Med 171 (1990) 465-475
135. Han S., Zhang X., Marinova E., Ozen Z., Bheekha-Escura R., Guo L., et al. Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response. Arthritis Rheum 52 (2005) 3202-3209
136. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
137. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 34 (2005) 7-11
138. Harashima S.-I., Horiuchi T., Hatta N., Morita C., Higuchi M., Sawabe T., et al. Outside-to-inside signal through the membraneTNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 166 (2001) 130-136
139. Haynes D.R., Barg E., Crott T.N., Holding C., Weedon H., Atkins G.J., et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 42 (2003) 123-134
140. Hehlgans T., and Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 (2005) 1-20
141. Higuchi M., and Aggarwal B. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 152 (1994) 3550-3558
142. Howarth P.H., Babu K.S., Arshad H.S., Lau L., Buckley M., McConnell W., et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60 (2005) 1012-1018
143. Hultgren O., Eugster H.-P., Sedgwick J.D., Korner H., and Tarkowski A. TNF/lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus. J Immunol 161 (1998) 5937-5942
144. Humira (adalimumab) prescribing information. Abbott Laboratories, North Chicago, IL (2007)
145. Hwang W.Y.K., and Foote J. Immunogenicity of engineered antibodies. Methods Humanized Antibodies Applications vol. 36 (2005) 3-10
146. Iizuka K., Chaplin D.D., Wang Y., Wu Q., Pegg L.E., Yokoyama W.M., et al. Requirement for membrane lymphotoxin in natural killer cell development. PNAS 96 (1999) 6336-6340
147. Isomaki P., Panesar M., Annenkov A., Clark J.M., Foxwell B.M.J., Chernajovsky Y., et al. Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface. J Immunol 166 (2001) 5495-5507
148. Ito D., Back T.C., Shakhov A.N., Wiltrout R.H., and Nedospasov S.A. Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment. J Immunol 163 (1999) 2809-2815
149. Jerne N.K. Towards a network theory of the immune system. Ann Immunol (Paris) 125C (1974) 373-389
150. Joosten L.A.B., Helsen M.M.A., Saxne T., van de Loo F.A.J., and van den Berg W.B. IL-1aβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-á blockade only ameliorates joint inflammation. J Immunol 163 (1999) 5049-5055
151. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-a, by human macrophages. J Immunol 160 (1998) 3513-3521
152. Kaine J.L., Kivitz A.J., Birbara C., and Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 34 (2007) 272-279
153. Kapetanovic M.C., Saxne T., Sjoholm A., Truedsson L., Jonsson G., and Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology 45 (2006) 106-111
154. Kavanaugh A.F., Greenwald M., Zizic T., Rao V., Fischkoff F., Hoffman R., et al. Treatment with adalimumab (D2E7) does not affect normal immune responsiveness. Arthritis Rheum 46 (2002) S132 (Suppl)
155. Kavanaugh A., Tutuncu Z., and Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 18 (2006) 347-353
156. Kay J., Matteson E.L., Dasgupta B., Nash P., Durez P., Hall S., et al. One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: a phase II, randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 Suppl 2123 (2006) S833
157. Kaymakcalan Z., Beam C., and Salfeld J. Murine model for assessing adalimumab, infliximab, and etanercept to prevent polyarthritis. Ann Rheum Dis 62 Suppl 1 (2003) 136-137
158. Kaymakcalan Z., Sakorafas P., Bose S., and Scesney S. Adalimumab, etanercept, and infliximab bind to soluble and transmembrane TNF with similar affinities. Ann Rheum Dis 65 Suppl II (2006) 458
159. Kaymakcalan Z., Kalghatgi L., and Xiong L. Differential TNF-neutralizing potencies of adalimumab, etanercept, and infliximab. Ann Rheum Dis 65 Suppl II (2006) 458
160. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10 (1991) 4025-4031
161. Keystone E.C. Safety of biologic therapies: an update. J Rheumatol Suppl 32 (2005) 8-12
162. Keystone E., Kavanaugh A., Sharp J., Tannenbaum H., Hua Y., Teoh L., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab a human anti-tumor necrosis factor monoclonal antibody in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
163. Kim E.Y., and Teh H.-S. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol 173 (2004) 4500-4509
164. Kirchner S., Holler E., Haffner S., Andreesen R., and Eissner G. Effect of different tumor necrosis factor TNF reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28 (2004) 67-74
165. Kitaura H., Zhou P., Kim H.-J., Novack D.V., Ross F.P., and Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115 (2005) 3418-3427
166. Klareskog L., and McDevitt H. Rheumatoid arthritis and its animal models: the role of TNF-[alpha] and the possible absence of specific immune reactions. Curr Opin Immunol 11 (1999) 657-662
167. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
168. Knight D., Trinh H., Le J., Siegel S., Shealy D., McDonough M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30 (1993) 1443-1453
169. Koch A.E. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62 (2003) 60-67
170. Koenders M.I., Joosten L.A.B., and van den Berg W.B. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 65 (2006) iii29-iii33
171. Kohno T., Louie J.S., and Stevens S.R. Differences in Fc receptor and C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action. J Invest Dermatol 124 4 (2005) A111
172. Kohno T., Tam L., Ting T., Bass R.B., and Stevens S.R. Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. Arthritis Rheum 52 9 (2005) S562-S563
173. Kollias G. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34 (2005) 3-6
174. Kollias G., Kontoyiannis D., Douni E., and Kassiotis G. The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized 'anti-TNF' therapies. Curr Dir Autoimmun 5 (2002) 30-50
175. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398
176. Koshy P.J., Henderson N., Logan C., Life P.F., Cawston T.E., and Rowan A.D. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 61 (2002) 704-713
177. Kotake S.l., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes. Arthritis Rheum 44 (2001) 1003-1012
178. Kraan M.C., De Koster B.M., Elferink J.G.R., Post W.J., Breedveld F.C., and Tak P.P. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 43 (2000) 1488-1495
179. Kraan M.C., Reece R.J., Barg E.C., Smeets T.J.M., Farnell J., Rosenburg R., et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 43 (2000) 1820-1830
180. Kratz A., Campos-Neto A., Hanson M., and Ruddle N. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 183 (1996) 1461-1472
181. Kristensen M., Chu C.Q., Eedy D.J., Feldmann M., Brennan F.M., and Breathnach S.M. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 94 (1993) 354-362
182. Kruger-Krasagakis S., Galanopoulos V.K., Giannikaki L., Stefanidou M., and Tosca A.D. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol 154 (2006) 460-466
183. Kruithof E., De Rycke L., Roth J., Mielants H., Van den Bosch F., De Keyser F., et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 52 (2005) 3898-3909
184. Ksontini R.M.D., MacKay S.L.D.P., and Moldawer L.L.P. Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. Arch Surg 133 (1998) 558-567
185. Kubota A., Hasegawa K., Suguro T., and Koshihara Y. Tumor necrosis factor-á promotes the expression of ostoprotegrin in rheumatoid synovial fibroblasts. J Rheumatol 31 (2004) 426-435
186. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W.L., et al. Effectiveness of TNF-á blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 41 (2002) 1303-1307
187. Landewé R., van der Heijde D., Klareskog L., van Vollenhoven R., and Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 54 (2006) 3119-3125
188. Lange F., Bajtner E., Rintisch C., Nandakumar K.S., Sack U., and Holmdahl R. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann Rheum Dis 64 (2005) 599-605
189. Lee C.K., Lee E.Y., Chung S.M., Mun S.H., Yoo B., Moon H.B., et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappa-B, osteoprotegerin, and receptor activator of nuclear factor kappa-B ligand. Arthritis Rheum 50 (2004) 3831-3843
190. Lee S.J., and Kavanaugh A. Adalimumab for the treatment of rheumatoid arthritis. Therapy 2 (2005) 13-21
191. Legler D.F., Micheau O., Doucey M.-A., Tschopp J., and Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNF[alpha]-mediated NF-[kappa]B activation. Immunity 18 (2003) 655-664
192. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
193. Liepinsh D.J., Grivennikov S.I., Klarmann K.D., Lagarkova M.A., Drutskaya M.S., Lockett S.J., et al. Novel lymphotoxin alpha (LTalpha) knockout mice with unperturbed tumor necrosis factor expression: reassessing LTalpha biological functions. Mol Cell Biol 26 (2006) 4214-4225
194. Lin W.W., and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117 (2007) 1175-1183
195. Lipsky P.E., van der Heijde D.M.F.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl J Med 343 (2000) 1594-1602
196. Listing J., Strangfeld A., Kary A., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
197. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93 (2004) 2645-2668
198. Lorenz H.M., Antoni C., Valerius T., Repp R., Grünke M., Schwerdtner N., et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis short term cellular and molecular effects. J Immunol 156 (1996) 1646-1653
199. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., and Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1457
200. Luther S.A., Bidgol A., Hargreaves D.C., Schmidt A., Xu Y., Paniyadi J., et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 169 (2002) 424-433
201. Maini R.N., and Feldmann M. How does infliximab work in rheumatoid arthritis?. Arthritis Res 4 (2002) S22-S28
202. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., MacFarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
203. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
204. Maini R.N., Taylor P.C., Paleolog E., Charles P., Ballara S., Brennan F.M., et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 58 Suppl 1 (1999) I56-I60
205. Malaviya R., Sun Y., Tan J.K., Wang A., Magliocco M., Yao M., et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 55 (2006) 590-597
206. Malaviya R., Sun Y., Tan J.K., Magliocco M., and Gottlieb A.B. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. J Drugs Dermatol 5 (2006) 890-893
207. Manes T.D., Pober J.S., and Kluger M.S. Endothelial cell-T lymphocyte interactions: iP-10 stimulates rapid transendothelial migration of human effector but not central memory CD4+T cells. Requirements for shear stress and adhesion molecules. Transplantation 82 (2006) S9-S14
208. Mangashetti L.S., Khapli S.M., and Wani M.R. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa and calcium signaling. J Immunol 175 (2005) 917-925
209. Markham T., Mullan R., Golden-Mason L., Rogers S., Bresnihan B., FitzGerald O., et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 54 (2006) 1003-1012
210. Maurice M.M., Van Der Graaff W.L., Leow A., Breedveld F.C., Van Lier R.A.W., and Verweij C.L. Treatment with monoclonal anti-tumor necrosis factor α antibody results in an accumulation of Th1 CD4+T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 42 (1999) 2166-2173
211. Mayo M.W., and Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470 (2000) M55-M62
212. McDevitt H., Munson S., Ettinger R., and Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 4 Suppl 3 (2002) S141-S152
213. Mease P.J., Ritchlin C.T., Martin R.W., Gottlieb A.B., Baumgartner S.W., Burge D.J., et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 31 (2004) 1356-1361
214. Medvedev A.E., Espevik T., Ranges G., and Sundan A. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem 271 (1996) 9778-9784
215. Micheau O., and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003) 181-190
216. Mitoma H., Horiuchi T., and Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 26 (2004) 934-935
217. Mitoma H., Horiuchi T., Hatta N., Tsukamoto H., Harashima S.-I., Kikuchi Y., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[945]. Gastroenterology 128 (2005) 376-392
218. Mohler K., Torrance D., Smith C., Goodwin R., Stremler K., Fung V., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151 (1993) 1548-1561
219. Monastra G., Cabrelle A., Zambon A., Rosato A., Macino B., Collavo D., et al. Membrane form of TNFalpha induces both cell lysis and apoptosis in susceptible target cells. Cell Immunol 171 (1996) 102-110
220. Montesinos M.C., Yap J.S., Desai A., Posadas I., McCrary C.T., and Cronstein B.N. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 43 (2000) 656-663
221. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5 (1999) 828-831
222. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 (1993) 1675-1680
223. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141-147
224. Moreland L.W., Bucy R.P., Weinblatt M.E., Mohler K.M., Spencer G.G.T., and Chatham W.W. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 103 (2002) 13-21
225. Möttönen M., Heikkinen J., Mustonen L., Isomäki P., Luukkainen R., and Lassila O. CD4+CD25+T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 140 (2005) 360-367
226. Mueller R.B., Skapenko A., Grunke M., Wendler J., Stuhlmuller B., Kalden J.R., et al. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum 52 (2005) 451-460
227. Murphy M., Walter B.N., Pike-Nobile L., Fanger N.A., Guyre P.M., Browning J.L., et al. Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ 5 (1998) 497-505
228. Mussener A., Litton M.J., Lindroos E., and Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 107 (1997) 485-493
229. Nesbitt A.M., Fossati G., and Brown D.T. Comparison of certolizumab pegol, etanercept, adalimumab, and infliximab: effect on lipopolysaccharide-induced cytokine production by human peripheral blood monocytes. Am J Gastroenterol 101 Suppl 2 (2006) S420-S470
230. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34 (2005) 12-18
231. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74 (2005) 13-18
232. Nickoloff B., Karabin G.D., Barker J.N., Griffiths C.E., Sarma V., Mitra R.S., et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138 (1991) 129-140
233. Nikas S.N., Voulgari P.V., Alamanos Y., Papadopoulos C.G., Venetsanopoulou A.I., Georgiadis A.N., et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 65 (2006) 257-260
234. Nishikawa S.-I., Honda K., Vieira P., and Yoshida H. Organogenesis of peripheral lymphoid organs. Immunol Rev 195 (2003) 72-80
235. O'Gradaigh D., Ireland D., Bord S., and Compston J.E. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor á, interleukin 1, and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 63 (2004) 354-359
236. Paleolog E.M., Hunt M., Elliott M.J., Feldmann M., Maini R.N., and Woody J.N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 39 (1996) 1082-1091
237. Paleolog E.M., Young S., Stark A.C., McCloskey R.V., Feldmann M., and Maini R.N. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1258-1265
238. Palmqvist P., Lundberg P., Persson E., Johansson A., Lundgren I., Lie A., et al. Inhibition of hormone and cytokine-stimulated ostoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 281 (2006) 2414-2429
239. Pasparakis M., Alexopoulou L., Episkopou V., and Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184 (1996) 1397-1411
240. Pasparakis M., Alexopoulou L., Grell M., Pfizenmaier K., Bluethmann H., and Kollias G. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. PNAS 94 (1997) 6319-6323
241. Paul A.T., Gohil A.M., and Bhutani K.K. Modulating TNF-alpha signaling with natural products. Drug Discov Today 11 (2006) 725-732
242. Petit A.R., Walsh N.C., Manning C., Goldring S.R., and Gravallese E.M. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 45 (2006) 1068-1076
243. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
244. Pittoni V., Bombardieri M., Spinelli F.R., Scrivo R., Alessandri C., Conti F., et al. Anti-tumour necrosis factor (TNF) {alpha} treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 61 (2002) 723-725
245. Radaev S., and Sun P. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol 38 (2002) 1073-1083
246. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46 (2002) 785-792
247. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110 (2002) 1419-1427
248. Remicade (infliximab) prescribing information. Centocor, Inc. Malvern, PA (2006)
249. Rennert P., Browning J., Mebius R., Mackay F., and Hochman P. Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs. J Exp Med 184 (1996) 1999-2006
250. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., and Schwarz E.M. Mechanisms of TNF-a- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111 (2003) 821-831
251. Roach D.R., Briscoe H., Saunders B., France M.P., Riminton S., and Britton W.J. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J Exp Med 193 (2001) 239-246
252. Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364 (1993) 798-802
253. Roux-Lombard P., Punzi L., Hasler F., Bas S., Todesco S., Gallati H., et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 36 (1993) 485-489
254. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
255. Salfeld J., Kaymakcalan Z., Tracey D., Robert A., and Kamen R. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum 41 (1998) S57
256. Sandborn W. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 5 (2005) 10-18
257. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
258. Sands B.E. Why do anti-tumor necrosis factor antibodies work in Crohn's disease?. Rev Gastroenterol Disord 4 (2004) S10-S17
259. Santora L.C., Kaymakcalan Z., Sakorafas P., Krull I.S., and Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299 (2001) 119-129
260. Sasso E.H., Barber C.V., Nardella F.A., Yount W.J., and Mannik M. Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The Cγ2-Cγ3 interface region contains the major determinants. J Immunol 40 (1988) 3098-3107
261. Saxne T., Palladino M.J., Heinegard D., Talal N., and Wollheim F. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31 (1988) 1041-1045
262. Scallon B.J., Moore M.A., Trinh H., Knight D.M., and Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 (1995) 251-259
263. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.-Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 (2002) 418-426
264. Schett G., Hayer S., Zwerina J., Redlich K., and Smolen J.S. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Practice Rheum 1 (2005) 47-53
265. Schett G. Rheumatoid arthritis: inflammation and bone loss. Wien Med Wochenschr 156 (2006) 34-41
266. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Spencer-Green G.T., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 889-894
267. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial. Arthritis Rheum 54 (2006) 92
268. Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21 (2004) 415-428
269. Schottelius A.J.G., Moldawer L.L., Dinarello C.A., Asadullah K., Sterry W., and Edwards C.K. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol 13 (2004) 193-222
270. Schreiber S., Rutgeerts P., Fedorak R.N., Khaliq-Kareemi M., Kamm M.A., Boivin M., et al. A randomized, placebo-controlled trial of certolizumab pegol CDP870 for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
271. Serbina N.V., Salazar-Mather T.P., Biron C.A., Kuziel W.A., and Pamer E.G. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19 (2003) 59-70
272. Shen C., Assche G.V., Colpaert S., Maerten P., Geboes K., Rutgeerts P., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21 (2005) 251-258
273. Shen C.P., Van Assche G.P.M.D., Rutgeerts P.P.M.D., and Ceuppens J.L.P.M.D. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 12 (2006) 22-28
274. Smeets T.J.M., Kraan M.C., van Loon M.E., and Tak P.-P. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 48 (2003) 2155-2162
275. Smolen J.S., Han C., Bala M., Maini R.N., Kalden J.R., van der Heijde D., et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52 (2005) 1020-1030
276. Smolen J.S., van der Heijde D.M., St. Clair E.W., Emery P., Bathon J.M., Keystone E., et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54 (2006) 702-710
277. Smookler D.S., Mohammed F.F., Kassiri Z., Duncan G.S., Mak T.W., and Khokha R. Cutting edge: tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 176 (2006) 721-725
278. Smyth M.J., Johnstone R.W., Cretney E., Haynes N.M., Sedgwick J.D., Korner H., et al. Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. J Immunol 163 (1999) 1350-1353
279. St. Clair E.W., Wagner C.L., Fasanmade A.A., Wang B., Schaible T., Kavanaugh A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1451-1459
280. St. Clair E.W., van der Heidje D., Smolen J.S., Maini R., Bathon J., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
281. Straub R.H., Härle P., Sarzi-Puttini P., and Cutolo M. Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. Arthritis Rheum 54 (2006) 2039-2046
282. Suffredini A.F., Reda D., Banks S.M., Tropea M., Agosti J.M., and Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155 (1995) 5038-5045
283. Tak P.P. Effects of infliximab treatment on rheumatoid synovial tissue. J Rheumatol Suppl 74 (2005) 31-34
284. Tak P.P., and Firestein G.S. Apoptosis in rheumatoid arthritis. In: Winkler J.D. (Ed). Apoptosis and Inflammation (Progress in Inflammation Research) (1999), Birkhäuser Publishing Ltd, Basel 149-162
285. Tak P.P., Smeets T.J.M., Daha M.R., Kluin P.M., Meijers K.A.E., Brand R., et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 40 (1997) 217-225
286. Tak P.P., Taylor P.C., Breedveld F.C., Smeets T.J., Daha M.R., Kluin P.M., et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39 (1996) 1077-1081
287. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43 (2000) 259-269
288. Takemura S., Braun A., Crowson C., Kurtin P.J., Cofield R.H., O'Fallon W.M., et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167 (2001) 1072-1080
289. Tas S.W., Remans P.H.J., Reedquist K.A., and Tak P.P. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Dis 11 (2005) 581-611
290. Taylor P.C., Peters A.M., Paleolog E., Chapman P.T., Elliott M.J., McCloskey R., et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 43 (2000) 38-47
291. ten Hove T., van Montfrans C., Peppelenbosch M.P., and van Deventer S.J.H. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
292. Terslev L., Torp-Pedersen S., Qvistgaard E., Kristoffersen H., Rogind H., Danneskiold-Samsoe B., et al. Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 62 (2003) 178-181
293. Thorbecke G., Shah R., Leu C., Kuruvilla A., Hardison A., and Palladino M. Involvement of endogeneous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89 (1992) 7375-7379
294. Tutuncu Z., Kavanaugh A., Zvaifler N., Corr M., Deutsch R., and Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 52 (2005) 2693-2696
295. Ulfgren A.K., Lindblad S., Klareskog L., Andersson J., and Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 54 (1995) 654-661
296. Ulfgren A.K., Andersson U., Engström M., Klareskog L., Maini R.N., and Taylor P.C. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 43 (2000) 2391-2396
297. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124 (2003) 177-185
298. Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Shevach E.M., and Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108 (2006) 253-261
299. Van den Brande J., Braat H., van den Brink G., Versteeg H., Bauer C., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
300. van der Laken C.J., Voskuyl A.E., Roos J.C., Stigter van Walsum M., de Groot E.R., Wolbink G., et al. Imaging and serum analysis of immune complex formation of radiolabeled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66 (2006) 253-256
301. Van Deventer S. Tumour necrosis factor and Crohn's disease. Gut 40 (1997) 443-448
302. van Lent P.L., Blom A.B., Grevers L., Sloetjes A., and van den Berg W.B. TLR-4 Induced FcγR expression potentiates early onset of joint inflammation and cartilage destruction during immune complex arthritis: tlr4 largely regulates FcγR expression by IL-10. Ann Rheum Dis 66 (2006) 334-340
303. van Lieshout A.W.T., Barrera P., Smeets R.L., Pesman G.J., van Riel P.L.C.M., van den Berg W.B., et al. Inhibition of TNFalpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNFalpha blockade in rheumatoid arthritis. Ann Rheum Dis 64 (2005) 408-414
304. van Vollenhoven R., Harju A., Brannemark S., and Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 62 (2003) 1195-1198
305. Vigna-Pérez M., Abud M.C., Portillo S.H., Alvarado S.B., Cuevas O.E., Moreno V.R., et al. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 141 (2005) 372-380
306. Vis M., Havaardsholm E.A., Haugeberg G., Uhlig T., Voskuyl A.E., van de Stadt R.J., et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 1495-1499
307. Voon D.C., Subrata L.S., Karimi M., Ulgiati D., and Abraham L.J. TNF and phorbol esters induce lymphotoxin-beta expression through distinct pathways involving Ets and NF-kappaB family members. J Immunol 172 (2004) 4332-4341
308. Walsh N.C., Crotti T.N., Goldring S.R., and Gravallese E.M. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208 (2005) 228-251
309. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23 (2005) 787-819
310. Ware C., Crowe P., Grayson M., Androlewicz M., and Browning J. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149 (1992) 3881-3888
311. Wee S., Pascual M., Eason J.D., Schoenfeld D.A., Phelan J., Boskovic S., et al. Biological effects and fate of a soluble, dimeric, 80-Kda tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy 1. Transplantation 63 (1997) 570-577
312. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
313. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
314. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
315. Weir N., Athwal D., Brown D., Foulkes R., Kollias G.l., Nesbitt A., et al. A new generation of high-affinity humanized PEGylated Fab' fragment anti-tumor necrosis factor-(alpha) monoclonal antibodies. Therapy 3 (2006) 535-545
316. Weisman M.H., Moreland L.W., Furst D.E., Weinblatt M.E., Keystone E.C., Paulus H.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25 (2003) 1700-1721
317. Weyand C., Seyler T., and Goronzy J. B cells in rheumatoid synovitis. Arthritis Res Ther 7 (2005) S9-S12
318. Williams R., Feldmann M., and Maini R. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89 (1992) 9784-9788
319. Williams-Abbott L., Walter B.N., Cheung T.C., Goh C.R., Porter A.G., and Ware C.F. The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha 1beta 2 heterotrimeric ligand. J Biol Chem 272 (1997) 19451-19456
320. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., De Groot E., Nurmohamed M.T., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 711-715
321. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1740-1751
322. Wu Q., Sun Y., Wang J., Lin X., Wang Y., Pegg L.E., et al. Signal via lymphotoxin-betaR on bone marrow stromal cells is required for an early checkpoint of NK cell development. J Immunol 166 (2001) 1684-1689
323. Yang X., Tisch R., Singer S., Cao Z., Liblau R., Schreiber R., et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice.I. The early development of autoimmunity and the diabetogenic process. J Exp Med 180 (1994) 995-1004
324. Yao Z., Li P., Zhang Q., Schwarz E.M., Keng P., Arbini A., et al. Tumor necrosis factor-α increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 281 (2006) 11846-11855
325. Zeltser R., Valle L., Tanck C., Holyst M.M., Ritchlin C., and Gaspari A.A. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 137 (2001) 893-899
326. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45 (2005) 490-497
327. Zhou H., Buckwalter M., Boni J., Mayer P., Raible D., Wajdula J., et al. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42 (2004) 267-276
328. Zhou H., Jang H., Fleischmann R.M., Bouman-Thio E., Xu Z., Marini J.C., et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-a monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 47 (2007) 383-396
329. Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor á treatment. Arthritis Rheum 46 (2002) 1744-1753
330. Zwerina J., Hayer S., Tohidast-Akrad M., Bergmeister H., Redlich K., Feige U., et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50 (2004) 277-290